Vol. 273, Issue 6, G1297-G1303, December 1997
Adenosine kinase inhibitor GP515 attenuates hepatic leukocyte
adhesion after hemorrhagic hypotension
Clemens
Bauer1,
Maarten G.
Bouma2,
Isa
Herrmann3,
Frans A. J. M.
Van
Den Wildenberg2,
Gary S.
Firestein4,
Ingo
Marzi3, and
Wim A.
Buurman2
Departments of 1 Anesthesiology
and 3 Trauma Surgery, University
of Saarland, D-66421 Homburg/Saar, Germany;
2 Department of Surgery,
Maastricht University, Maastricht, The Netherlands; and
4 Gensia, Inc., San Diego,
California 92121
 |
ABSTRACT |
Adhesion of
leukocytes to the vascular endothelium hallmarks a key event in
neutrophil-mediated organ injury after ischemia-reperfusion. The
autacoid adenosine has been shown to inhibit activated neutrophil function and to interfere with leukocyte-endothelial adherence. Its
therapeutic use in ischemia-reperfusion, however, has been limited by
severe cardiovascular side effects. We therefore investigated the
effects of the adenosine kinase inhibitor GP515 in vivo on hepatic
leukocyte-endothelial interactions in a rat model of hemorrhagic hypotension and resuscitation, using intravital microscopy. Rats were
pretreated with either GP515 (0.25 mg/kg) or saline in a randomized and
blinded manner and subjected to pressure-controlled hemorrhagic
hypotension at a mean arterial pressure of 40 mmHg for 60 min followed
by 5 h of resuscitation. Five hours after resuscitation in
saline-treated animals, firm leukocyte-sinusoidal adhesion was strongly
enhanced in the periportal and midzonal sublobular regions, and
sinusoidal diameters were also markedly reduced. Compared with saline
treatment, GP515 significantly attenuated shock and
resuscitation-induced leukocyte adhesion in both sublobular regions.
Moreover, although GP515 did not significantly affect macrohemodynamical and hematological parameters, it enlarged narrowed sinusoidal diameters and tended to improve sinusoidal blood flow. We
propose that the adenosine-regulating agent GP515 has a therapeutic potential to attenuate ischemia-reperfusion-induced inflammation by
capitalizing on the beneficial anti-inflammatory effects of endogenous
adenosine.
hemorrhagic shock; liver; leukocyte-endothelial interactions; resuscitation; intravital microscopy; rat
 |
INTRODUCTION |
ISCHEMIA-REPERFUSION INJURY is an important
pathological event that may result from restoration of blood
circulation in a variety of serious clinical conditions, such as acute
arterial obstruction, major vascular surgery, and hemorrhagic shock.
Hypovolemic shock, as occurs after trauma or complex surgical
procedures, followed by resuscitation, essentially represents a
"whole body" ischemia-reperfusion insult and is often clinically
associated with the development of a systemic inflammatory response
syndrome and multiple-organ dysfunction syndrome (2, 21). Central to
the pathogenesis of the inflammatory response to ischemia-reperfusion are the activation of neutrophils and their subsequent adhesion to the
vascular endothelium (40). Strategies aimed at attenuating the
inflammatory cascades elicited during ischemia-reperfusion include the
use of antioxidants, platelet-activating factor antagonists, anti-cytokine monoclonal antibodies (MAbs), and MAbs to vascular and
leukocyte adhesion molecules. During recent years, however, the
anti-inflammatory potential of the endogenous metabolite adenosine has
become an important focus of attention of studies seeking alternative
therapeutical strategies to prevent or inhibit the detrimental
inflammatory response after ischemia-reperfusion. In this context,
adenosine has been termed a "retaliatory metabolite" (29). The
reported anti-inflammatory effects of adenosine include inhibition of
cytokine release (7, 8, 17, 31, 34), expression of endothelial adhesion
molecules (8), leukocyte endothelial adhesion (18), and neutrophil
function (6, 10, 13). Although numerous in vitro studies have
demonstrated the antiadhesive effects of adenosine, few reports exist
on the effects of adenosine on adhesion during postischemic
conditions in vivo (23, 30). However, the therapeutic use of adenosine
and its analogs has been limited by severe side effects, such as
hypotension and bradycardia, as well as a short half-life. The strategy
underlying the use of adenosine-regulating agents is to enhance
endogenous adenosine concentrations at local sites of inflammation,
thus enhancing the beneficial anti-inflammatory effects of adenosine while minimizing systemic toxicity. Under physiological conditions, adenosine is generated by dephosphorylation of AMP. This step is
reverted by the enzyme adenosine kinase, which phosphorylates adenosine
to AMP. Therefore one possibility for interference with the adenosine
metabolism to increase adenosine concentration is to inhibit the
rephosphorylation of adenosine by blocking adenosine kinase. GP515 is a
novel adenosine kinase inhibitor, whose anti-inflammatory actions have
indeed been related to enhancement of endogenous concentrations of
adenosine (6, 12, 18, 33). This compound has been reported to provide
protection from mortality in two rodent models of septic shock without
displaying systemic side effects (17). Currently, however, its
potential therapeutic use in ischemia-reperfusion has not been
investigated. As outlined above, enhanced leukocyte-endothelial
adhesion is a pivotal early step in the development of postischemic
neutrophil-mediated injury of various target organs, such as the liver
and lungs (24, 37, 38). We therefore examined the effects of the
adenosine-regulating agent GP515 on leukocyte-endothelial interactions
in the rat liver after hemorrhagic hypotension and resuscitation as a
model of hemorrhagic shock, using intravital microscopy as described by Marzi et al. (26).
 |
MATERIALS AND METHODS |
Animals.
The experiments were performed using female Sprague-Dawley rats
(200-250 g body wt), obtained from Charles River, Sulzfeld, Germany. The study design was approved by the local veterinarian ethics
committee. Rats had free access to standard rat food and water until the day of the experiment. The animals were anesthetized by
intraperitoneal injection of pentobarbital sodium (50 mg/kg). Body temperature was maintained at 37 ± 0.5°C using a
temperature-controlled warming plate (Conrad Electronic, Hirschau,
Germany).
Surgical preparation.
All surgical preparations were performed under aseptic conditions.
After induction of anesthesia and dermal disinfection, the rats were
tracheotomized and intubated to maintain free airways and to allow
spontaneous breathing. The animals were then instrumented for invasive
monitoring of hemodynamical parameters as follows. The left carotid
artery was cannulated with a thermistor-tipped 1.5-F catheter, which
was advanced into the aortic arc for measurement of cardiac output (CO)
by the transpulmonary thermodilution method (Cardiotherm 500, Columbus
Instruments, Columbus, OH). The right internal jugular vein was
cannulated with polyethylene tubing (0.4 × 0.8 mm, Portex, Hythe,
UK) for infusion of GP515 and resuscitation fluids. The left femoral
artery was cannulated with polyethylene tubing (0.4 × 0.8 mm) for continuous invasive monitoring of the mean arterial
blood pressure (MAP) and heart rate (HR) using a pressure transducer
(Hellige SMK 154-9, Freiburg, Germany). This line was used for
shock induction and to take blood samples for laboratory analyses
(blood gas analysis by ABL, Radiometer, Copenhagen, Denmark;
hematological parameters by Sysmex 2000, Digitana, Frankfurt, Germany).
Blood samples (300 µl each) were drawn at baseline, before shock
induction, at the end of shock, and after 1 and 5 h of resuscitation.
After shock, blood losses due to sampling were isovolumetrically
substituted with shed blood.
Experimental groups.
Animals were randomly assigned to two shock groups and two nonshock
control groups, receiving the adenosine kinase inhibitor GP515 (kindly
provided by Gensia, San Diego, CA) or an equal amount of vehicle
(saline) in a blinded manner. Thus four experimental groups were
formed: a shock/saline group (S-S), a shock/GP515 group (S-GP), a
control/saline group (C-S), and a control/GP515 group (C-GP). GP515 was
administered at a dose of 0.25 mg/kg diluted in 2 ml saline and infused
intravenously during a 30-min period followed by an additional 30 min
of steady state before shock induction. In preliminary dose-finding
studies, 0.25 mg/kg infused over a 30-min period was found to be the
critical dose to produce only a slight, nonsignificant initial
hypotensive effect, with MAP stable thereafter. The experimental group
assignment is summarized in Table 1. Two
additional shock groups were investigated to examine the effects of
GP515 on shock-induced inflammation and liver injury at 2 days after
shock. Animals of the 2-day shock groups
(n = 5 each) were treated either with
GP515 or saline. After 2 days, the serum activity of liver
transaminases and organ edema were measured and compared with a
time-matched sham-control group.
Hemorrhagic hypotension and resuscitation.
After pretreatment with either GP515 or vehicle, hemorrhagic
hypotension was induced within 5 min by blood withdrawal from the
femoral arterial line until MAP was 40 mmHg. Shed blood was citrated to
inhibit coagulation. The shock model used was pressure controlled;
i.e., if MAP was >45 mmHg, additional blood was drawn. Hypotension
was maintained at 40 mmHg for 60 min, and subsequently 60% of shed
blood was retransfused. The animals were additionally resuscitated with
lactated Ringer solution with twice the shed blood volume in the 1st h,
once the shed blood volume in the 2nd and 3rd h, and with 10 ml · kg
1 · h
1
in the 4th and 5th h. This resuscitation regimen was previously shown
to sufficiently restore systemic circulation after hemorrhagic hypotension (3). Control animals were instrumented in an identical manner but were not subjected to hypotension and subsequent
resuscitation.
Intravital microscopy.
Five hours after the start of resuscitation from shock or at the
corresponding time point in control animals, the hepatic microcirculation was investigated by intravital microscopy. The abdomen
was opened by a midline laparotomy, and the left liver lobe was
mobilized after dissection of the hepatic ligaments. The animal was
positioned onto its left side on a specially designed Plexiglas stage,
which allowed gentle exteriorization of the left liver lobe, with its
lower plane surface uppermost. The liver surface was covered with
plastic foil and continuously superfused with saline at 37°C to
prevent exsiccation. The hepatic microcirculation was then investigated
using a Nikon MM-11 epifluorescence microscope (Tokyo, Japan) with a
100-W mercury lamp, a 545 nm excitation filter, a ×10/0.30 water
immersion objective, a 0.7-2.25 zoom objective, a ×12
ocular, and a final magnification of ×330. The experiments were
recorded with a low-light charge-coupled device camera (FK6990, Pieper,
Schwerte, Germany), which was connected through a serial time-date
generator (VTG 33, FOR-A Company, Tokyo, Japan) with a SVHS
video-recording system (Panasonic FS-1, Tokyo, Japan). Acridine orange
(1 mg/ml in saline, Sigma, St. Louis, MO) as fluorescence marker of
leukocytes was injected intravenously as bolus of 0.1 mg per recorded
liver lobule. The microcirculation and leukocyte-endothelial
interactions in five liver lobules were observed and recorded during 30 s for off-line evaluation. Next, five central venules were brought into
the center of the image, and the pericentral region was recorded for
comparable determination of sinusoidal diameters at distances of 90 µm from the central vein.
On completion of the experiments, the livers were harvested, and wet
weight was determined. Next, the organs were dried at 60°C for 24 h
and weighed again to determine wet-to-dry ratio as a marker of organ
edema.
Evaluation.
The recorded sequences of intravital liver microscopy were evaluated
off-line by an independent observer blinded to experimental group
assignment.
Leukocyte adhesion was determined as the number of leukocytes per
square millimeter of liver surface for each of the three different
sublobular fields of the liver acinus as described by Rappaport (32).
According to recent previous studies (3, 26), two distinct types of
leukocyte adhesion were differentiated: reversible, temporary adhesion
(adhesion time: <20 s; mean adhesion time: 1-3 s), and mostly
irreversible, firm adhesion (adhesion time: >20 s).
The hepatic microcirculation was quantitated by assessment of
sinusoidal diameters and estimated sinusoidal blood flow, as determined
by leukocyte velocity measurements using a computer-supported morphometrical image analysis system (Lobulus, Medvis, Homburg, Germany). Flow was calculated under the assumption of circular diameters of sinusoids using the following equation: F = vL ·
· (Ds/2)2,
where F is flow,
vL is leukocyte
velocity, and Ds
is sinusoidal diameter.
Statistical analysis.
Data are presented as mean ± SE. Differences between groups were
tested by analysis of variance and post hoc Student-Newman-Keuls test.
Differences between various time points within one group were tested by
paired t-test.
P < 0.05 was considered
statistically significant.
 |
RESULTS |
Hemodynamical parameters.
At baseline, MAP, HR, and CO were identical in all experimental groups
(Fig. 1). Infusion of 0.25 mg/kg GP515 over
a 30-min period resulted in a moderate, nonsignificant reduction of MAP from 125.4 ± 5.6 to 102.9 ± 7.8 mmHg in the control group
(C-GP) and from 128.9 ± 4.6 to 103.3 ± 6.2 mmHg in the shock
group (S-GP). Also, after infusion of GP515, MAP in both GP515-treated
groups did not differ significantly from both saline-treated control groups at the corresponding time point
(t = 30 min). Similarly, intravenous
administration of GP515 did not affect HR and CO before shock. Compared
with baseline, a slight, but nonsignificant increase in CO was observed
during the 1st h of the experiment, which was, however, identical in
all experimental groups. Hemorrhagic hypotension was induced and
maintained constantly at 40 mmHg for 60 min, resulting in a reduction
of HR and CO that was the same in the saline- and GP515-treated groups.
Resuscitation completely restored shock-induced hemodynamic changes in
both shock groups, with MAP, HR, and CO being identical compared with
both control groups. Moreover, no significant differences in these
hemodynamical parameters were observed between saline- and
GP515-treated animals.
Laboratory analysis.
Before induction of shock, pH, blood gases, hemoglobin concentration
(Hb), hematocrit (Hct), and leukocyte count were comparable in all
experimental groups (Table 2). Compared
with the end of steady state (t = 60 min), shock resulted in a significant elevation of arterial
PO2 and a reduction of arterial
PCO2 as well as reduced Hb and Hct.
These changes were not altered by pretreatment with GP515. At the end
of shock, arterial PO2 and
PCO2, Hb, and Hct were significantly
altered in shocked compared with nonshocked animals. During
reperfusion, no significant differences with regard to these parameters
were observed among any of the experimental groups. Neither in control
animals nor in shock animals did GP515 affect the laboratory parameters
determined.
View this table:
[in this window]
[in a new window]
|
Table 2.
pH, blood gases, hemoglobin concentration, hematocrit, and leukocyte
count in experimental groups before shock
|
|
Liver wet-to-dry ratio and transaminases.
Liver wet-to-dry weight ratios revealed no differences among all
experimental groups at 5 h after shock (data not shown). However, the
significant increase in liver wet-to-dry ratio at 2 days after shock
was prevented by GP515. In addition, at this time point, the
shock-induced increase of serum activity of the transaminase aspartate
aminotransferase (AST) was significantly reduced in the GP515 group
(Fig. 2).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
Serum activity of transaminases and liver wet-to-dry weight ratios at 2 days after hemorrhagic hypotension and resuscitation. Data are given as
magnitude of increase of baseline values. AST, aspartate
aminotransferase; ALT, alanine aminotransferase; 2D-C, 2-day control
group; 2D-S, 2-day shock group; 2D-GP, 2-day shock/GP515 group.
* P < 0.05 vs. 2D-C and
2D-GP.
|
|
Leukocyte adhesion.
Five hours after resuscitation from shock or at the corresponding time
point in control animals, temporary leukocyte adhesion was identical in
treated as well as untreated control and shock groups, ranging from 8.6 ± 0.7 to 9.7 ± 0.5% of the total number of sinusoidal
leukocytes, and displayed no differences between the various sublobular
regions (data not shown).
The number of leukocytes firmly adhering to the endothelial wall was
comparable in both control groups (Fig. 3),
with the highest adhesion numbers in the periportal region (C-S: 394 ± 16 leukocytes/mm2, and C-GP:
352 ± 27 leukocytes/mm2). In
the nontreated shock group (S-S), firm leukocyte adhesion was
significantly enhanced in the periportal (1,032 ± 95 leukocytes/mm2) and midzonal
(387 ± 35 leukocytes/mm2)
regions of the liver acinus compared with both control groups. Also, in
the pericentral field, the number of adhering leukocytes was 311 ± 77/mm2 in the S-S group, compared
with 126 ± 54 /mm2 in the C-S
group (P < 0.05) and 172 ± 62/mm2 in the C-GP group
(P > 0.05). Pretreatment with GP515
markedly attenuated leukocyte adhesion after shock, with a significant reduction in the periportal as well as the midzonal field to 562 ± 22 and 286 ± 37 leukocytes/mm2, respectively.
Moreover, GP515 reduced shock-induced firm leukocyte adhesion in these
two fields to a level comparable with saline-treated controls. GP515
also reduced shock-induced adhesion in the pericentral region to 224 ± 89 leukocytes/mm2,
but without reaching statistical significance compared with saline-treated shock animals.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 3.
GP515 reduces firm leukocyte adhesion in liver 5 h after hemorrhagic
hypotension and resuscitation, as determined by intravital microscopy.
* P < 0.05 vs. C-S;
# P < 0.05 vs. S-S.
|
|
Hepatic microcirculation.
Mean sinusoidal diameter in the saline-treated control group was 11.6 ± 0.3 µm, and was nonsignificantly increased by ~7% in the
GP515-treated control group (Fig.
4A).
After shock and resuscitation, sinusoids were markedly narrowed to a
mean diameter of 7.8 ± 0.2 µm. In comparison, pretreatment with
GP515 partly prevented this sinusoidal narrowing, resulting in a mean
sinusoidal diameter of 9.8 ± 0.1 µm, a significant increase of
~26%. In parallel, GP515 tended to enhance reduced sinusoidal blood
flow after shock (Fig. 4B), almost
reaching statistical significance (37.5 ± 1.1 and 50.8 ± 3.5 µl/s in S-S vs. S-GP, respectively;
P = 0.06). In control animals,
however, GP515 did not affect sinusoidal blood flow.
 |
DISCUSSION |
In the present study we have determined the effects of pretreatment
with the adenosine kinase inhibitor GP515 on firm leukocyte-endothelial adhesion in the liver after 1 h of hemorrhagic shock followed by 5 h of
reperfusion. Previous studies using this animal model have revealed two
different patterns of leukocyte adhesion in the liver after hemorrhagic
shock. First, temporary (short-term) adhesion is maximally elevated in
the 1st h of resuscitation and declines thereafter (26). This type of
reversible leukocyte-endothelial interaction may be the correlate of
postcapillary leukocyte rolling and represents an early step in
neutrophil recruitment to inflammatory sites. Second, firm (long-term)
adhesion, also referred to as leukocyte sticking, increases gradually
during the reperfusion period and is significantly elevated 5 h after
resuscitation from shock (3). Adherence of neutrophils to the vascular
endothelium is an important step in neutrophil-mediated injury of
endothelial cells, a key pathological event in ischemia-reperfusion
(40). Although initial rolling is considered a prerequisite for firm adherence (22), it is the strong adhesive neutrophil-endothelial interaction that is thought to create a sequestered microenvironment in
which activated neutrophils release proteolytic enzymes and reactive
oxygen metabolites that cause the endothelial damage, eventually
resulting in increased microvascular permeability and organ edema (39,
40). Therefore, to study firm adhesion of leukocytes to the liver
sinusoids, we selected the 5-h reperfusion time frame. Indeed, our
present results confirm the extent of increase of leukocyte adhesion as
well as these earlier observed adhesion patterns, with firm adhesion
highly elevated in both shock groups compared with both control groups
and temporary adhesion being identical in all experimental groups.
Also, the sublobular adhesion pattern with increasing numbers of firmly
adhering leukocytes in the pericentral, midzonal, and periportal
regions, respectively, was consistent with previous results in this
model (26). Firm leukocyte adhesion to sinusoidal endothelium as
observed in this study was previously shown not to be due to mechanical
trapping of leukocytes in narrowed sinusoid but was suggested to be a
receptor-specific mechanism (4). The results of the study cited clearly
indicate the involvement of adhesion receptors such as intercellular
adhesion molecule-1 (ICAM-1) and the corresponding CD11b/CD18 complex
in the process of firm leukocyte adhesion (4).
The most prominent finding of this study is that GP515 strongly
attenuated shock-induced firm adhesion of leukocytes to the sinusoidal
endothelium. As reported by Vedder et al. (37, 38) and Mileski et al.
(28), inhibition of CD18-dependent firm neutrophil adherence
effectively reduces neutrophil-mediated injury to the lungs, liver, and
gastrointestinal tract after hemorrhagic shock in rodents as well as in
subhuman primates. Similarly, in isolated hepatic ischemia-reperfusion
models, it has been established that massive neutrophil infiltration
contributes to postischemic liver injury (24, 36). Although in the
aforementioned hemorrhagic shock models gross organ injury was evident
after long-term resuscitation, in the present study no gross liver
edema, as determined by liver wet-to-dry ratios, was present after 5 h
of resuscitation. However, at 2 days after shock, a significant
increase in liver wet-to-dry ratio was observed, possibly due to tissue
injury by activated and transmigrated leukocytes. GP515 had protective
effects at this time point indicated by reduced liver wet-to-dry ratio
and significantly reduced serum activity of AST.
The observed antiadhesive effect of the adenosine-regulating agent
GP515 is consistent with reported effects of adenosine and adenosine
A2 receptor agonists on
neutrophil-endothelial interactions in vitro (9, 11, 16, 18) and in
vivo (1, 23, 30, 33). Although we did not measure in vivo adenosine
levels in this study, GP515 has been demonstrated to enhance local
endogenous adenosine concentrations in vitro (18) and ex vivo (6), as well as in vivo (12). Although activation of neutrophil
A2 receptors has been implicated
in the antiadhesive effect of adenosine, it has not currently been
established which specific types of leukocyte adhesion molecules are
affected by adenosine. Firestein et al. (18) have observed that
adenosine interferes with L-selectin-mediated adhesion and does not
affect CD18-dependent adhesion in a static adhesion assay. Others have
demonstrated that in vitro integrin-mediated adhesion can also be
modulated by adenosine (14, 41). Interestingly, adenosine has been
shown to inhibit stimulated upregulation of the CD11/CD18 integrin on
human neutrophils in vitro (41). Because GP515 attenuated the firm
adhesive leukocyte-endothelial interactions, our results would be in
support of altered integrin-mediated adhesion, although we cannot rule
out an early effect on selectin-mediated rolling. The present results
are paralleled by previous similar findings in this same model obtained
with the natural glycoprotein neutrophil inhibitory factor, which
inhibits CD11b/CD18-mediated adhesion (4).
Adenosine A2 receptors are thought
to couple unifocally to adenylate cyclase, with activation resulting in
enhanced generation of intracellular adenosine 3',5'-cyclic
monophosphate (cAMP) (35). Elevated neutrophil intracullular cAMP has
indeed been related to inhibition of CD11b/CD18 surface expression in
vitro (14), thus supporting a role for
A2 receptors in downmodulating
postischemic integrin-mediated adhesion. In line with this, the
cAMP-raising agent pentoxifylline attenuated hemorrhagic shock-induced
leukocyte-sinusoidal adhesion in this animal model in an identical
fashion as described here for GP515 (27).
Although neutrophils have clearly been identified as targets for the
anti-inflammatory actions of adenosine, endothelial cells have not been
ruled out as potential targets for adenosine. On the contrary,
adenosine has been shown to inhibit expression of E-selectin and
vascular cell adhesion molecule-1, by activated human endothelial cells
in vitro (8). Also, the adenosine analog 3-deazaadenosine inhibits
ICAM-1 biosynthesis in tumor necrosis factor-
-stimulated cultured
human endothelium (25). It therefore remains to be determined whether
interference of adenosine with endothelial expression of adhesion
molecules is involved in the inhibition of neutrophil-endothelial
interactions in vivo.
A second interesting observation in this study is that GP515 displayed
a tendency to improve local microcirculation in the liver after
resuscitation from shock. Although sinusoidal diameters in nontreated
shock animals were significantly reduced compared with sham-operated
animals, GP515 significantly enhanced sinusoidal diameters after shock.
GP515 also slightly enlarged sinusoidal diameters in control animals
but had a relatively stronger effect on sinusoidal diameter after
shock. In parallel, although sinusoidal blood flow was significantly
reduced after shock, GP515 tended to improve sinusoidal flow after
shock, almost reaching statistical significance
(P = 0.06), but was without effect on
blood flow in control animals. Although adenosine is known to exert
negative chronotropic and dromotropic effects (20) and to cause
hypotension (5), GP515, compared with saline treatment, did not affect the cardiovascular parameters MAP, HR, and CO in this study. Moreover, systemic hematological parameters were not altered by GP515. Together, these data suggest that GP515 acts to enhance endogenous adenosine at
its local site of formation, thereby limiting systemic side effects and
at the same time capitalizing on well-recognized beneficial microcirculatory effects of adenosine during ischemia-reperfusion (15,
19).
In summary, using an experimental model that allowed direct
visualization of hepatic leukocyte-endothelial interactions and microcirculation, we have demonstrated that systemic administration of
the adenosine-regulating agent GP515 has significant antiadhesive and
mild beneficial microcirculatory effects in the early inflammatory response to hemorrhagic hypotension and resuscitation, which are paralleled by reduced liver injury at the long term. Our results point
to a possible therapeutic potential of GP515 and possibly other
adenosine-regulating agents (39-41) in the treatment of
ischemia-reperfusion injury.
 |
ACKNOWLEDGEMENTS |
Present of address of G. S. Firestein: Div. of Rheumatology,
University of California, San Diego, School of Medicine, La Jolla, CA
92093.
 |
FOOTNOTES |
Address for reprint requests: C. Bauer, Dept. of Anesthesiology and
Critical Care Medicine, University of Saarland Medical School, D-66421
Homburg/Saar, Germany.
Received 25 November 1996; accepted in final form 22 August 1997.
 |
REFERENCES |
1.
Asako, H.,
R. E. Wolf,
and
D. N. Granger.
Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate.
Gastroenterology
104:
31-37,
1993[Medline].
2.
Baue, A. E.
Multiple organ failure, multiple organ dysfunction syndrome, and the systemic inflammatory response syndrome
where do we stand? (Editorial)
Shock
2:
385-397,
1994[Medline].
3.
Bauer, C.,
I. Marzi,
M. Bauer,
H. Fellger,
and
R. Larsen.
Interleukin-1 receptor antagonist attenuates leukocyte-endothelial interactions in the liver following hemorrhagic shock in the rat.
Crit. Care Med.
23:
1099-1105,
1995[Medline].
4.
Bauer, C.,
S. Siaplaouras,
H. Soule,
and
I. Marzi.
A natural glycoprotein (NIF) inhibiting CD11b/CD18 reduces leukocyte adhesion in the liver following hemorrhagic shock.
Shock
4:
187-192,
1995[Medline].
5.
Belardinelli, L.,
J. Linden,
and
R. M. Berne.
The cardiac effects of adenosine.
Prog. Cardiovasc. Dis.
32:
73-97,
1989[Medline].
6.
Bouma, M. G.,
T. M. M. A. Jeunhomme,
M. A. Dentener,
N. N. Voitenok,
F. A. J. M. van den Wildenberg,
and
W. A. Buurman.
Adenosine inhibits neutrophil degranulation in activated human whole blood. Involvement of adenosine A2 and A3 receptors.
J. Immunol.
158:
5400-5408,
1997[Abstract].
7.
Bouma, M. G.,
R. K. Stad,
F. A. J. M. van den Wildenberg,
and
W. A. Buurman.
Differential regulatory effects of adenosine on cytokine release by activated human monocytes.
J. Immunol.
153:
4159-4168,
1994[Abstract].
8.
Bouma, M. G.,
F. A. van den Wildenberg,
and
W. A. Buurman.
Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells.
Am. J. Physiol.
270 (Cell Physiol. 39):
C522-C529,
1996[Abstract/Free Full Text].
9.
Bullough, D. A.,
M. J. Magill,
G. S. Firestein,
and
K. M. Mullane.
Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes.
J. Immunol.
155:
2579-2586,
1995[Abstract].
10.
Cronstein, B. N.,
R. I. Levin,
J. Belanoff,
G. Weissmann,
and
R. Hirschhorn.
Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells.
J. Clin. Invest.
78:
760-770,
1986.
11.
Cronstein, B. N.,
R. I. Levin,
M. Philips,
R. Hirschhorn,
S. B. Abramson,
and
G. Weissmann.
Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors.
J. Immunol.
148:
2201-2206,
1992[Abstract].
12.
Cronstein, B. N.,
D. Naime,
and
G. Firestein.
The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine.
Arthritis Rheum.
38:
1040-1045,
1995[Medline].
13.
Cronstein, B. N.,
E. D. Rosenstein,
S. B. Kramer,
G. Weissmann,
and
R. Hirschhorn.
Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils.
J. Immunol.
135:
1366-1371,
1985[Abstract].
14.
Derian, C. K.,
R. J. Santulli,
P. E. Rao,
H. F. Solomon,
and
J. A. Barrett.
Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators.
J. Immunol.
154:
308-317,
1995[Abstract].
15.
Engler, R.
Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia.
Federation Proc.
46:
2407-2412,
1987[Medline].
16.
Felsch, A.,
K. Stocker,
and
U. Borchard.
Phorbol ester-stimulated adherence of neutrophils to endothelial cells is reduced by adenosine A2 receptor agonists.
J. Immunol.
155:
333-338,
1995[Abstract].
17.
Firestein, G. S.,
D. Boyle,
D. A. Bullough,
H. E. Gruber,
F. G. Sajjadi,
A. Montag,
B. Sambol,
and
K. M. Mullane.
Protective effect of an adenosine kinase inhibitor in septic shock.
J. Immunol.
152:
5853-5859,
1994[Abstract].
18.
Firestein, G. S.,
D. A. Bullough,
M. D. Erion,
R. Jimenez,
M. Ramirez Weinhouse,
J. Barankiewicz,
C. W. Smith,
H. E. Gruber,
and
K. M. Mullane.
Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins.
J. Immunol.
154:
326-334,
1995[Abstract].
19.
Forman, M. B.,
C. E. Velasco,
and
E. K. Jackson.
Adenosine attenuates reperfusion injury following regional myocardial ischaemia.
Cardiovasc. Res.
27:
9-17,
1993[Free Full Text].
20.
Fredholm, B. B.,
and
A. Sollevi.
Cardiovascular effects of adenosine.
Clin. Physiol.
6:
1-21,
1986[Medline].
21.
Goris, R. J. A.,
T. P. A. Te Boekhorst,
J. K. S. Nuytinck,
and
J. S. F. Gimbrere.
Multiple-organ failure.
Arch. Surg.
120:
1109-1115,
1985[Abstract].
22.
Granger, D. N.,
and
P. Kubes.
The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion.
J. Leukoc. Biol.
55:
662-675,
1994[Abstract].
23.
Grisham, M. B.,
L. A. Hernandez,
and
D. N. Granger.
Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation.
Am. J. Physiol.
257 (Heart Circ. Physiol. 26):
H1334-H1339,
1989[Abstract/Free Full Text].
24.
Jaeschke, H.,
A. Farhood,
and
C. W. Smith.
Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo.
FASEB J.
4:
3355-3359,
1990[Abstract].
25.
Jurgensen, C. H.,
B. E. Huber,
T. P. Zimmerman,
and
G. Wolberg.
3-Deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells.
J. Immunol.
144:
653-661,
1990[Abstract].
26.
Marzi, I.,
C. Bauer,
R. Hower,
and
V. Bühren.
Leukocyte-endothelial cell interactions in the liver after hemorrhagic shock in the rat.
Circ. Shock
40:
105-114,
1993[Medline].
27.
Marzi, I.,
M. Maier,
C. Herzog,
and
M. Bauer.
Influence of pentoxifylline and albifylline on liver microcirculation and leukocyte adhesion after hemorrhagic shock in the rat.
J. Trauma
40:
90-96,
1996[Medline].
28.
Mileski, W. J.,
R. K. Winn,
N. B. Vedder,
T. H. Pohlman,
J. M. Harlan,
and
C. L. Rice.
Inhibition of CD18-dependent neutrophil adherence reduces organ injury after hemorrhagic shock in primates.
Surgery
108:
206-212,
1990[Medline].
29.
Newby, A. C.
Adenosine and the concept of retaliatory metabolites.
Trends Biochem. Sci.
9:
42-44,
1984.
30.
Nolte, D.,
A. Lorenzen,
H. A. Lehr,
F. J. Zimmer,
K. N. Klotz,
and
K. Messmer.
Reduction of postischemic leukocyte-endothelium interaction by adenosine via A2 receptor.
Naunyn Schmiedebergs Arch. Pharmacol.
346:
234-237,
1992[Medline].
31.
Parmely, M. J.,
W. W. Zhou,
C. K. Edwards III,
D. R. Borcherding,
R. Silverstein,
and
D. C. Morrison.
Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge.
J. Immunol.
151:
389-396,
1993[Abstract].
32.
Rappaport, A. M.
Acinar units and the pathophysiology of the liver.
In: The Liver. Morphology, Biochemistry, Physiology, edited by C. Rouiller. London: Academic, 1963, vol. I, p. 265-328.
33.
Rosengren, S.,
G. W. Bong,
and
G. S. Firestein.
Anti-inflammatory effects of an adenosine kinase inhibitor. Decreased neutrophil accumulation and vascular leakage.
J. Immunol.
154:
5444-5451,
1995[Abstract].
34.
Sajjadi, F. G.,
K. Takabayashi,
A. C. Foster,
R. C. Domingo,
and
G. S. Firestein.
Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors.
J. Immunol.
156:
3435-3442,
1996[Abstract].
35.
Stiles, G. L.
Adenosine receptors.
J. Biol. Chem.
267:
6451-6454,
1992[Abstract/Free Full Text].
36.
Suzuki, S.,
L. H. Toledo Pereyra,
F. Rodriguez,
and
F. Lopez.
Role of Kupffer cells in neutrophil activation and infiltration following total hepatic ischemia and reperfusion.
Circ. Shock
42:
204-209,
1994[Medline].
37.
Vedder, N. B.,
B. W. Fouty,
R. K. Winn,
J. M. Harlan,
and
C. L. Rice.
Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock.
Surgery
106:
509-516,
1989[Medline].
38.
Vedder, N. B.,
R. K. Winn,
C. L. Rice,
E. Y. Chi,
K.-E. Arfors,
and
J. M. Harlan.
A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits.
J. Clin. Invest.
81:
939-944,
1988.
39.
Weiss, S. J.
Tissue destruction by neutrophils.
N. Engl. J. Med.
320:
365-377,
1989[Medline].
40.
Welbourn, C. R.,
G. Goldman,
I. S. Paterson,
C. R. Valeri,
D. Shepro,
and
H. B. Hechtman.
Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil.
Br. J. Surg.
78:
651-655,
1991[Medline].
41.
Wollner, A.,
S. Wollner,
and
J. B. Smith.
Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (CD11b/CD18) expression on FMLP-stimulated neutrophils.
Am. J. Respir. Cell Mol. Biol.
9:
179-185,
1993.
AJP Gastroint Liver Physiol 273(6):G1297-G1303
0193-1857/97 $5.00
Copyright © 1997 the American Physiological Society